JNJ 61187191

Drug Profile

JNJ 61187191

Alternative Names: Ad35-RSV-FA2; Ad35.RSV.FA2; JNJ-61187191; JNJ-61187191-AAA; Respiratory syncytial virus - Crucell

Latest Information Update: 18 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Crucell
  • Developer Crucell; Janssen Pharmaceuticals
  • Class Respiratory syncytial virus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Respiratory syncytial virus infections

Most Recent Events

  • 01 Sep 2016 Crucell Holland completes a phase I trial for Respiratory syncytial virus infections (Prevention, In volunteers) in USA (NCT02561871)
  • 01 Jun 2016 Crucell completes a phase-I clinical trial in Respiratory syncytial virus infections (In volunteers) in USA (IM) (NCT02440035)
  • 01 Sep 2015 Crucell Holland initiates a phase I trial for Respiratory syncytial virus infections (Prevention, In volunteers) in USA (NCT02561871)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top